If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-23. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
The Orange Box is a video game compilation containing five games developed and published by Valve. Two of the games included—Half-Life 2 and its first stand-alone expansion, Episode One—had previously been released in 2004 and 2006 as separate products. Three new games were also included in the compilation: the second stand-alone expansion, Half-Life 2: Episode Two; the puzzle game Portal; and Team Fortress 2, the sequel to Team Fortress Classic. Valve also released a soundtrack containing music from the games within the compilation. A separate product entitled The Black Box was planned, which would have included only the new games, but was later canceled. The Orange Box was released for Windows and the Xbox 360 in October 2007, while the PlayStation 3 version, developed by EA UK, was released in December 2007. The Xbox 360 and PlayStation 3 versions were published by Electronic Arts. A digital Orange Box pack, containing the five games, was released in May 2010 for Mac OS X following the release of Steam for the platform, while a similar version for Linux followed after the Steam's clients release for Linux in early 2013. The Orange Box received widespread critical acclaim, with Portal being recognized as a surprise favorite of the package. The PlayStation 3 version of The Orange Box, however, was criticized for containing several technical shortcomings that were not present in the other versions, only a few of which were fixed through a single patch.
Both the δDs of sea water and the fractionations associated with hyptophyte biochemistry (εbio) are fairly well understood, so alkenones can be readily used to observe the secondary effect of salinity on δD. There is a well established positive linear correlation between salinity and εl/w, on the order of a ~3‰ change in fractionation per salinity unit. Hypothesized mechanisms for this effect include enrichment of D in intracellular water due to reduced exchange with extracellular water at higher salinity, removal of H from intracellular water due to increased production of solutes to maintain osmotic pressure at higher salinity, and lower haptophyte growth rates at higher salinity Alkenone δDs have been used successfully to reconstruct past salinity changes in the Mediterranean Sea, Black Sea, Panama Basin, and Mozambique Channel. As an extension of salinity, this data was also used to draw further conclusions about ancient environments, such as ancient freshwater flooding events, and the evolution of plankton in response to environmental changes
== Coupled reactions == Since energy is released when ATP is broken down, energy is required to rebuild or resynthesize it. The building blocks of ATP synthesis are the by-products of its breakdown; adenosine diphosphate (ADP) and inorganic phosphate (Pi). The energy for ATP resynthesis comes from three different series of chemical reactions that take place within the body. Two of the three depend upon the food eaten, whereas the other depends upon a chemical compound called phosphocreatine. The energy released from any of these three series of reactions is utilized in reactions that resynthesize ATP. The separate reactions are functionally linked in such a way that the energy released by one is used by the other. Three processes can synthesize ATP:
Gaddafi married his first wife, Fatiha al-Nuri, in 1969. They had one son, Muhammad Gaddafi (born 1970); their relationship was strained, and they divorced in 1970. Gaddafi's second wife was Safia Farkash, née el-Brasai, a former nurse from the Obeidat tribe, born in Bayda. They met in 1969, after his ascension to power, when he was hospitalized with appendicitis; he claimed that it was love at first sight. The couple remained married until his death. Together they had seven biological children: Saif al-Islam Gaddafi (1972–2026), Al-Saadi Gaddafi (born 1973), Mutassim Gaddafi (1974–2011), Hannibal Muammar Gaddafi (born 1975), Aisha Gaddafi (born 1976), Saif al-Arab Gaddafi (1982–2011), and Khamis Gaddafi (1983–2011). He also adopted two children, Hana Gaddafi and Milad Gaddafi. Several of his sons gained a reputation for lavish and anti-social behaviour in Libya, which proved a source of resentment toward his administration. At least three of his cousins were prominent figures in Gaddafi's regime. Ahmed Gaddaf al-Dam is Libya's former Special Envoy to Egypt and a leading figure of the Gaddafi regime. Mansour Dhao was his chief of security and led the People's Guard. Sayyid Gaddaf al-Dam was a brigadier general and described as the second most powerful person in Libya in the 1980s. Saif al-Islam Gaddafi, the son who was considered to be Gaddafi's main heir, was assassinated in February 2026.
=== St–Sz === Frank Stahl (1929–2025), US molecular biologist known for the Meselson-Stahl experiment Donald F. Steiner (1930–2014). American biochemist at the University of Chicago, who made ground breaking discoveries in the treatment of diabetes. Member Natl. Acad. Sci. USA Joan Steitz FRS (foreign associate) (b. 1941). American biochemist at Yale University, best known for her work on RNA. Member Natl. Acad. Sci. USA. Thomas A. Steitz FRS (foreign associate) (1940–2018). American biochemist at Yale University, best known for his pioneering work on the ribosome. Nobel Prize in Chemistry, 2009. Member Natl. Acad. Sci. USA. Marjory Stephenson FRS (one of the first two women elected) (1885-1948). British biochemist and microbiologist at Cambridge University, most widely remembered for her seminal book, Bacterial Metabolism. Audrey Stevens (1932–2010). American biochemist at Oak Ridge National Laboratory, co-discoverer of RNA polymerase. Member Natl. Acad. Sci. USA. Bruce Stone (1928–2008). Australian biochemist known for work in cereal and grass polysaccharides. Foundation Professor of Biochemistry at La Trobe University (1972–1993). Lubert Stryer (1938–2024). American biophysicist at Stanford who pioneered the use of fluorescence spectroscopy, particularly Förster resonance energy transfer, to monitor the structure and dynamics of biological macromolecules. He is best known for his textbook Biochemistry. Member Natl. Acad. Sci. USA. Paul K.
Sources: en.wikipedia.org
== Influences and musical gear == Ron has had a wide variety of influences over the years. He enjoys the guitar playing of Hank Marvin of The Shadows, Bob Bogle of The Ventures, Ritchie Blackmore (Deep Purple), Gary Moore, Dann Huff (Giant), Danny Gatton, Cub Koda (Brownsville Station) and loves heavy rock music (Lillian Axe, Giant, Alice in Chains and Stone Temple Pilots for instance). His guitar style has changed somewhat over the years as well. In the 1960s he played Fender Jazzmaster, Gibson ES-335 and Rickenbacker thru Fender and Ampeg Amps. During the hard rock/metal craze of the 1980s Ron wielded Charvel's and Ibanez guitars with Peavey Amplification. From 2005 to 2010 Ron's main axe was a custom-wired Fender Stratocaster (designed by legendary Syracuse musician, the late Dave Pasternack). He uses a combination of Peavey and Fender amps. Ron is a fan of Digitech pedalboards, and has used them widely throughout the nineties and the 2000s. He currently favors Paul Reed Smith and the newly designed Charvel guitars for live performances. Ron uses a specially modified Fender CyberTwin 212 amplifier and a Morley Wah Pedal. Ron Lauback has influenced many Syracuse-based artists over the years. Dan Elliott has stated in interviews that Ron and The Sabres influenced him to form his first band The Dimensions as well as the helping Jack Abert and John Wisnewski start The Monterays.
=== 1950–2000 === In the 1950s, thiazide diuretics were developed by Merck scientists Karl H. Beyer, James M. Sprague, John E. Baer, and Frederick C. Novello and led to the marketing of the first drug of this class, chlorothiazide, under the trade name Diuril in 1958. The research leading to the discovery of chlorothiazide, leading to "the saving of untold thousands of lives and the alleviation of the suffering of millions of victims of hypertension" was recognized by a special Public Health Award from the Lasker Foundation in 1975. In 1953, Merck & Co. merged with Philadelphia-based Sharp & Dohme, Inc., becoming the largest U.S. drugmaker. Sharp and Dohme had acquired H. K. Mulford Company in 1929, adding smallpox vaccines to its portfolio. The combined company kept the trade name Merck in the United States and Canada, and as Merck Sharp & Dohme (MSD) outside these two countries. In 1965, Merck & Co. acquired Charles Frosst Ltd. of Montreal (founded 1899), creating Merck-Frosst Canada, Inc., as its Canadian subsidiary and pharmaceutical research facility. Merck & Co. closed this facility in July 2010 but reemerged in 2011 as Merck Canada. Maurice Hilleman, a scientist at Merck, developed the first mumps vaccine in 1967, the first rubella vaccine in 1969, and the first trivalent measles, mumps, rubella (MMR vaccine) in 1971. The incidence of rubella-associated birth defects fell from up to 10,000 per year in the U.S. to zero in the aftermath of the rubella vaccine's development.
=== Cyclin-dependent kinases === Cyclin-dependent kinases (CDKs) are serine-threonine kinases which regulate progression through the eukaryotic cell cycle. CDKs are catalytically active only when bound to a regulatory cyclin. Animal cells contain at least nine distinct CDKs which bind to various cyclins with considerable specificity. CDK inhibitors (CKIs) block kinase activity in the cyclin-CDK complex to halt the cell cycle in G1 or in response to environmental signals or DNA damage. The activity of different CDKs activate cell signaling pathways and transcription factors that regulate key events in mitosis such as the G1/S phase transition. Earlier cyclin-CDK complexes provide the signal to activate subsequent cyclin-CDK complexes.
He was succeeded by Kazuo Ito as president. In April 2002, Ajinomoto reorganized itself into food, amino acid, and medicine divisions, and owned subsidiaries for frozen foods, fats, and oils. In February 2003, Ajinomoto and Unilever completed a joint venture agreement in six countries and regions of Asia. Because of this, Ajinomoto launched the brand VONO to replace its use of the Knorr brand, and in the process established its own brand identity. In July 2003, Ajinomoto bought the French company Orsan from the UK-based Tate and Lyle Group, renaming Orsan to AJI-NO-MOTO Foods, Europe. In November 2005, AJI-NO-MOTO Pharmaceuticals USA, Inc. was liquidated, and its assets and functions were merged into AJI-NO-MOTO Pharmaceuticals, Europe. In January 2006, Ajinomoto bought the cooking sauce and condiments manufacturer Amoy Food from the French dairy company Groupe Danone. In 2009, the company released "Ajinomoto" to commemorate the 100th anniversary of its foundation.
Gaddafi called for the Arab world to regain its dignity and assert a major place on the world stage, blaming Arab backwardness on stagnation resulting from Ottoman rule, European colonialism and imperialism, and corrupt and repressive monarchies. Gaddafi's Arab nationalist views led him to the pan-Arabist belief in the need for unity across the Arab world, combining the Arab nation under a single nation-state. To this end, he had proposed a political union with five neighbouring Arab states by 1974, although without success. In keeping with his views regarding Arabs, his political stance was described as nativist. Gaddafi also had international ambitions, wanting to export his revolutionary ideas throughout the world. Gaddafi saw his socialist Jamahiriyah as a model for the Arab, Islamic, and non-aligned worlds to follow, and in his speeches declared that his Third International Theory would eventually guide the entire planet. He nevertheless had minimal success in exporting the ideology outside of Libya. Along with Arab nationalism, anti-imperialism was also a defining feature of Gaddafi's regime during its early years. He believed in opposing Western imperialism and colonialism in the Arab world, including any Western expansionism through the form of Israel. He offered support to a broad range of political groups abroad that called themselves "anti-imperialist", especially those that set themselves in opposition to the United States. For many years, anti-Zionism was a fundamental component of Gaddafi's ideology.
Sources: en.wikipedia.org
British biochemist at the National Institute for Medical Research in Mill Hill, London, specializing in thyroid biochemistry. David Andrew Phoenix (b. 1966). British biochemist at London South Bank University, where he studies properties of biologically active amphiphilic peptides. Rodney Porter FRS (1917–1985). British biochemist at Oxford known for determining the chemical structure of antibodies. Addy Pross (b. 1945), Israeli-Australian researcher of abiogenesis from a chemistry perspective Frank W. Putnam (1917–2006). American biochemist at the Indiana University, who worked on the structure and function of blood proteins. Member Natl. Acad. Sci. USA.
== Mechanical stress and activity indicators == Examining the effects that activities has upon the skeleton allows the archaeologist to examine who was doing what kinds of labor, and how activities were structured within society. Labor within the household may be divided according to gender and age, or be based on other social structures. Human remains can allow archaeologists to uncover these patterns. Living bones are subject to Wolff's law, which states that bones are physically affected and remodeled by physical activity or inactivity. Increases in mechanical stress tend to produce thicker and stronger bones. Disruptions in homeostasis caused by nutritional deficiency or disease or profound inactivity/disuse/disability can lead to bone loss. While the acquisition of bipedal locomotion and body mass appear to determine the size and shape of children's bones, activity during the adolescent growth period seems to exert a greater influence on the size and shape of adult bones than exercise later in life. Muscle or ligament attachment sites on bones (entheses) are also considered to be impacted by habitual biomechanical loading, leading to the occurrence of various entheseal changes. These changes are routinely used in the field to study activity-patterns.
In contrast, siRNAs typically base-pair perfectly and induce mRNA cleavage only in a single, specific target. In Drosophila and C. elegans, miRNA and siRNA are processed by distinct Argonaute proteins and Dicer enzymes.
The CHON principle was born to meet this further process requirement, according to which all extractants and molecular reagents used in the developed processes have only to contain atoms of carbon (C), hydrogen (H), oxygen (O) and nitrogen (N), thus incinerable waste to easily release into the environment.
Protein structure is dynamic; the protein hemoglobin bends into slightly different forms as it facilitates the capture, transport, and release of oxygen molecules within mammalian blood. A single nucleotide difference within DNA can cause a change in the amino acid sequence of a protein. Because protein structures are the result of their amino acid sequences, some changes can dramatically change the properties of a protein by destabilizing the structure or changing the surface of the protein in a way that changes its interaction with other proteins and molecules. For example, sickle-cell anemia is a human genetic disease that results from a single base difference within the coding region for the β-globin section of hemoglobin, causing a single amino acid change that changes hemoglobin's physical properties. Sickle-cell versions of hemoglobin stick to themselves, stacking to form fibers that distort the shape of red blood cells carrying the protein. These sickle-shaped cells no longer flow smoothly through blood vessels, having a tendency to clog or degrade, causing the medical problems associated with this disease. Some DNA sequences are transcribed into RNA but are not translated into protein products—such RNA molecules are called non-coding RNA. In some cases, these products fold into structures which are involved in critical cell functions (e.g. ribosomal RNA and transfer RNA). RNA can also have regulatory effects through hybridization interactions with other RNA molecules (such as microRNA).
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.